# Tune Therapeutics

its TEMPO platform produced TUNE-401, an IV-delivered LNP-RNA epigenetic silencer that reported positive Phase 1b/2a proof-of-concept data at EASL 2026 as a first-in-class epigenetic therapy for hepatitis B.

Source: https://en.bioecon.ru/companies/tune-therapeutics/
Updated: 2026-07-03

- Country: United States

## Technologies

- [Epigenome editing](https://en.bioecon.ru/technology/epigenome-editing/)